The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA
TwoStep Therapeutics
Multi-specific peptide-drug conjugates that target several tumor integrins at once.
What they do
TwoStep Therapeutics develops polyspecific integrin-targeting peptide-drug conjugates for solid tumors, spun out of Stanford University. It announced a 62.5 million dollar Series A led by Insight Partners and Medical Excellence Capital on September 9, 2026, alongside FDA clearance of the IND for lead program TS-104, with a Phase 1 trial planned across six tumor types.
The record
- Vertical
- Oncology
- Sub-segment
- Peptide-drug conjugates
- Product type
- Diagnostics
- Stage
- Series A
- Headquarters
- San Carlos, United States
- Region
- North America
- Founded
- 2024
- Total funding
- $71.2M raised
Notable investors: Insight Partners, Medical Excellence Capital, M Ventures, Pfizer Ventures, NFX, 2048 Ventures.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The senolytic drug pipeline is narrowing toward a smaller set of credible candidates
Dr. Dereck Mush, MD, MBA
State Medicaid programmes are quietly becoming a testing ground for digital therapeutics coverage
Dr. Dereck Mush, MD, MBA
The Biophysical Tumor Barrier: Inside TriSalus's TriNav Advance Clearance and the Fluid Mechanics of Interventional Oncology
Dr. Dereck Mush, MD, MBA